Answers are grounded in this paper and cite their sources.
Review reveals advancement of HER2-targeted therapies in breast cancer, indicating challenges in resistance management and therapeutic strategies.
The treatment paradigm for HER2-expressing breast cancer is evolving rapidly. Trastuzumab deruxtecan has redefined management for both HER2-positive and the newly recognized HER2-low subgroups, while tucatinib offers a critical systemic option for central nervous system metastases. Optimal sequencing and resistance management remain critical challenges in this dynamic field. Nonetheless, HER2-targeted pharmacotherapy continues to advance rapidly, driven by innovative drug designs and strategic clinical developments.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: